

metastatic cancer is selected from multiple myeloma, melanoma, lung cancer, hepatocellular carcinoma, breast cancer, or prostate cancer.

25.-27. (canceled)

28. A pharmaceutical composition for treating glaucoma, the composition comprising an effective amount of the compound of claim 1 and a pharmaceutically acceptable excipient.

29.-30. (canceled)

31. A method of inhibiting death of a cell exhibiting mutant myocilin, the method comprising contacting the cell with a compound of claim 1.

32.-33. (canceled)

34. A method of treating a patient or animal suffering from glaucoma, the method comprising administration of an effective amount of a compound of claim 1 to the patient or animal suffering from the glaucoma.

35.-36. (canceled)

37. A composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier.

38. A pharmaceutical composition for treating metastatic cancer, the composition comprising an effective amount of the compound of claim 2 and a pharmaceutically acceptable excipient.

39. A method for inhibiting cell motility of a cancer cell, the method comprising contacting the cancer cell with a compound of claim 2.

40. A method of treating a patient or animal suffering from metastatic cancer, the method comprising administration of an effective amount of a compound of claim 2 to the patient or animal suffering from the metastatic cancer, wherein the metastatic cancer is selected from multiple myeloma, melanoma, lung cancer, hepatocellular carcinoma, breast cancer, or prostate cancer.

41. A pharmaceutical composition for treating glaucoma, the composition comprising an effective amount of the compound of claim 2 and a pharmaceutically acceptable excipient.

42. A method of inhibiting death of a cell exhibiting mutant myocilin, the method comprising contacting the cell with a compound of claim 2.

43. A method of treating a patient or animal suffering from glaucoma, the method comprising administration of an effective amount of a compound of claim 2 to the patient or animal suffering from the glaucoma.

44. A composition comprising a compound of claim 15 and a pharmaceutically acceptable carrier.

45. A pharmaceutical composition for treating metastatic cancer, the composition comprising an effective amount of the compound of claim 15 and a pharmaceutically acceptable excipient.

46. A method for inhibiting cell motility of a cancer cell, the method comprising contacting the cancer cell with a compound of claim 15.

47. A method of treating a patient or animal suffering from metastatic cancer, the method comprising administration of an effective amount of a compound of claim 15 to the patient or animal suffering from the metastatic cancer, wherein the metastatic cancer is selected from multiple myeloma, melanoma, lung cancer, hepatocellular carcinoma, breast cancer, or prostate cancer.

48. A pharmaceutical composition for treating glaucoma, the composition comprising an effective amount of the compound of claim 15 and a pharmaceutically acceptable excipient.

49. A method of inhibiting death of a cell exhibiting mutant myocilin, the method comprising contacting the cell with a compound of claim 15.

50. A method of treating a patient or animal suffering from glaucoma, the method comprising administration of an effective amount of a compound of claim 15 to the patient or animal suffering from the glaucoma.

* * * * *